Burning Rock Biotech Limited Stock price

Equities

BNR

US12233L1070

Healthcare Facilities & Services

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
0.7281 USD +4.01% Intraday chart for Burning Rock Biotech Limited +4.13% -21.71%
Sales 2021 508M 70.29M Sales 2022 563M 77.95M Capitalization 1.63B 226M
Net income 2021 -797M -110M Net income 2022 -971M -134M EV / Sales 2021 9.68 x
Net cash position 2021 1.41B 195M Net cash position 2022 857M 119M EV / Sales 2022 1.38 x
P/E ratio 2021
-7.92 x
P/E ratio 2022
-1.66 x
Employees 1,138
Yield 2021 *
-
Yield 2022
-
Free-Float 62.79%
More Fundamentals * Assessed data
Dynamic Chart
1 day+4.01%
1 week+4.13%
Current month-14.57%
1 month-12.70%
3 months-22.54%
6 months-21.54%
Current year-21.71%
More quotes
1 week
0.66
Extreme 0.6612
0.78
1 month
0.57
Extreme 0.5722
0.90
Current year
0.57
Extreme 0.5722
1.00
1 year
0.57
Extreme 0.5722
3.25
3 years
0.57
Extreme 0.5722
38.64
5 years
0.57
Extreme 0.5722
39.75
10 years
0.57
Extreme 0.5722
39.75
More quotes
Managers TitleAgeSince
Founder - 13-12-31
Chief Executive Officer 46 13-12-31
Director of Finance/CFO 40 18-12-31
Members of the board TitleAgeSince
Director/Board Member 61 16-07-31
Chief Executive Officer 46 13-12-31
Director/Board Member 53 14-05-31
More insiders
Date Price Change Volume
24-03-28 0.7281 +4.01% 14,223
24-03-27 0.7 0.00% 102,209
24-03-26 0.7 -1.56% 83,727
24-03-25 0.7111 -8.48% 8,995
24-03-22 0.777 +11.13% 28,242

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
  1. Stock
  2. Equities
  3. Stock Burning Rock Biotech Limited - Nasdaq